PE20060366A1 - AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS - Google Patents
AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTSInfo
- Publication number
- PE20060366A1 PE20060366A1 PE2005000583A PE2005000583A PE20060366A1 PE 20060366 A1 PE20060366 A1 PE 20060366A1 PE 2005000583 A PE2005000583 A PE 2005000583A PE 2005000583 A PE2005000583 A PE 2005000583A PE 20060366 A1 PE20060366 A1 PE 20060366A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- pyridin
- amine
- optionally substituted
- dopamine agonists
- Prior art date
Links
- 150000003927 aminopyridines Chemical class 0.000 title abstract 2
- 229940052760 dopamine agonists Drugs 0.000 title 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 abstract 1
- -1 3-PHENYLPROPYL Chemical class 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE AMINOPIRIDINA DE FORMULA (I), EN DONDE R1 Y R2 SON INDEPENDIENTEMENTE H Y ALQUILO(C1-C6); R3 ES (II), (III) Y (IV), EN DONDE A ES O, S O CH2; n ES 1 O 2; R4 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON 1 O 2 ALQUILO(C1-C6), OR7, FENILO Y HETEROARILO; R5 ESH O ALQUILO(C1-C6), OPCIONALMENTE SUSTITUIDO CON OR7; R6 ES H O ALQUILO(C1-C6); R7 ES R6 DONDE AL ALQUILO PUEDE SER SUSTITUIDO POR FENILO OPCIONALMENTE SUSTITUIDO. SON PREFERIDOS: 5-(MORFOLIN-2-IL)PIRIDIN-2-AMINA, 5-[(2S,5S)-5-METIL-4-(3-FENILPROPIL)MORFOLIN-2-IL}PIRIDIN-2-AMINA, 5-[(2S,5S)-4,5-DIETILMORFOLIN-2-IL}PIRIDIN-2-AMINA; ENTRE OTROS. ESTOS COMPUESTOS SON AGONISTAS SELECTIVOS DE LA DOPAMINA D3, Y SON UTILES EN EL TRATAMIENTO Y/O PREVENCION DE DISFUNCION SEXUAL FEMENINA O MASCULINA Y ENFERMEDADES RELACIONADASREFERS TO AMINOPYRIDINE DERIVATIVE COMPOUNDS OF FORMULA (I), WHERE R1 AND R2 ARE INDEPENDENTLY H AND ALKYL (C1-C6); R3 IS (II), (III) AND (IV), WHERE A IS O, S O CH2; n IS 1 O 2; R4 IS H OR ALKYL (C1-C6) OPTIONALLY SUBSTITUTED WITH 1 OR 2 ALKYL (C1-C6), OR7, PHENYL AND HETEROARYL; R5 ESH OR ALKYL (C1-C6), OPTIONALLY SUBSTITUTED WITH OR7; R6 IS HO (C1-C6) ALKYL; R7 IS R6 WHERE THE RENT CAN BE SUBSTITUTED BY OPTIONALLY SUBSTITUTED PHENYL. THE PREFERRED ARE: 5- (MORPHOLIN-2-IL) PYRIDIN-2-AMINE, 5 - [(2S, 5S) -5-METHYL-4- (3-PHENYLPROPYL) MORFOLIN-2-IL} PYRIDIN-2-AMINE, 5 - [(2S, 5S) -4,5-DIETHYLMORPHOLIN-2-IL} PYRIDIN-2-AMINE; AMONG OTHERS. THESE COMPOUNDS ARE SELECTIVE AGONISTS OF DOPAMINE D3, AND ARE USEFUL IN THE TREATMENT AND / OR PREVENTION OF FEMALE OR MALE SEXUAL DYSFUNCTION AND RELATED DISEASES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
| GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20060366A1 true PE20060366A1 (en) | 2006-05-15 |
Family
ID=34970000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000583A PE20060366A1 (en) | 2004-05-27 | 2005-05-25 | AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1758862A1 (en) |
| JP (1) | JP4198183B2 (en) |
| AP (1) | AP2006003824A0 (en) |
| AR (1) | AR049548A1 (en) |
| AU (1) | AU2005247699A1 (en) |
| BR (1) | BRPI0511571A (en) |
| CA (1) | CA2567935C (en) |
| EA (1) | EA200601982A1 (en) |
| EC (1) | ECSP067029A (en) |
| GT (1) | GT200500125A (en) |
| IL (1) | IL179314A0 (en) |
| MA (1) | MA28607B1 (en) |
| MX (1) | MXPA06013786A (en) |
| NL (1) | NL1029139C2 (en) |
| NO (1) | NO20065326L (en) |
| PA (1) | PA8635101A1 (en) |
| PE (1) | PE20060366A1 (en) |
| SV (1) | SV2005002129A (en) |
| TW (1) | TW200609216A (en) |
| UY (1) | UY28925A1 (en) |
| WO (1) | WO2005115985A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| MA33032B1 (en) | 2009-02-13 | 2012-02-01 | Bayer Schering Pharma Ag | Intensive primidines |
| CA3215310A1 (en) * | 2010-04-12 | 2011-10-20 | Supernus Pharmaceuticals Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| WO2013003769A2 (en) | 2011-06-30 | 2013-01-03 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and, methods |
| GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| SMT202100723T1 (en) | 2016-07-20 | 2022-01-10 | Novartis Ag | Aminopyridine derivatives and their use as selective alk-2 inhibitors |
| MY203080A (en) * | 2017-12-08 | 2024-06-07 | Boehringer Ingelheim Int | Imidazopyridine derivatives and the use thereof as medicament |
| AU2020270992B2 (en) * | 2019-04-12 | 2025-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| PE20230251A1 (en) | 2019-11-22 | 2023-02-07 | Incyte Corp | COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR |
| JP2023530316A (en) | 2020-06-16 | 2023-07-14 | インサイト・コーポレイション | ALK2 inhibitors for the treatment of anemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| GEP20074272B (en) * | 2002-12-10 | 2007-12-25 | Pfizer | Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction |
-
2005
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/en not_active Expired - Fee Related
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/en not_active Application Discontinuation
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/en unknown
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-17 EA EA200601982A patent/EA200601982A1/en unknown
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en not_active Ceased
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/en not_active Application Discontinuation
- 2005-05-24 GT GT200500125A patent/GT200500125A/en unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/en not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/en unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/en not_active Application Discontinuation
- 2005-05-26 NL NL1029139A patent/NL1029139C2/en not_active IP Right Cessation
- 2005-05-26 AR ARP050102169A patent/AR049548A1/en unknown
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/en unknown
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/en not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/en unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/en unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PA8635101A1 (en) | 2006-05-16 |
| ECSP067029A (en) | 2006-12-29 |
| WO2005115985A1 (en) | 2005-12-08 |
| NL1029139C2 (en) | 2006-06-19 |
| SV2005002129A (en) | 2005-12-13 |
| IL179314A0 (en) | 2007-03-08 |
| GT200500125A (en) | 2006-01-10 |
| AR049548A1 (en) | 2006-08-16 |
| EP1758862A1 (en) | 2007-03-07 |
| JP2008500331A (en) | 2008-01-10 |
| CA2567935A1 (en) | 2005-12-08 |
| MXPA06013786A (en) | 2007-01-25 |
| CA2567935C (en) | 2009-10-27 |
| TW200609216A (en) | 2006-03-16 |
| AP2006003824A0 (en) | 2006-12-31 |
| UY28925A1 (en) | 2005-12-30 |
| JP4198183B2 (en) | 2008-12-17 |
| NL1029139A1 (en) | 2005-11-30 |
| AU2005247699A1 (en) | 2005-12-08 |
| MA28607B1 (en) | 2007-05-02 |
| EA200601982A1 (en) | 2007-04-27 |
| BRPI0511571A (en) | 2008-01-02 |
| NO20065326L (en) | 2006-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070833A1 (en) | PYRIMIDINYL BENZOTHIOPHENE COMPOUNDS | |
| MY133385A (en) | Benzazoles: benzoxazoles, benzthiazole and benzimidazole derivatives | |
| PE20121157A1 (en) | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| PE20070136A1 (en) | COMPOUNDS DERIVED FROM N- (PYRIDIN-2-IL) -SULFONAMIDE AS INHIBITORS OF THE ENZYME 11-beta-HYDROXIESTEROID DEHIDROGENASE HUMAN TYPE 1 | |
| PE20091843A1 (en) | CATEPSIN C INHIBITORS | |
| PE20061353A1 (en) | SULFONAMIDE-THIAZOLOPYRIDINE COMPOUNDS AS GLUCOCINASE ACTIVATORS | |
| AR004002A1 (en) | COMPOSITION USEFUL ESPECIALLY FOR THE TREATMENT AND PROTECTION OF DOMESTIC ANIMALS INFESTED OR LIKELY TO BE INFESTED BY PARASITES | |
| PE20060937A1 (en) | SULFONYLBENZIMIDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR 2 (CB2) AGONISTS | |
| PE20080318A1 (en) | DICETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS | |
| PE20081836A1 (en) | PIPERIDINE DERIVATIVES AS INHIBITORS OF FATTY ACID SYNTHASE | |
| PE20060241A1 (en) | 2-QUINOLYL-OXAZOLES SUBSTITUTED AS PDE4 INHIBITORS | |
| PE20050864A1 (en) | HETEROCICLYLAMINE COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1 | |
| PE20121506A1 (en) | TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS | |
| PE20130385A1 (en) | DERIVATIVES OF NAFT-2-ILACETIC ACID TO TREAT AIDS | |
| PE20090290A1 (en) | PYRROLOPYRIDINE DERIVATIVES AS BACE INHIBITORS | |
| WO2008012733A3 (en) | Method and composition for permanently shaping hair | |
| PE20090601A1 (en) | PYRIDIN-IL-OXY-PYRIDINES DERIVATIVES AS ALK5 INHIBITORS | |
| PE20120691A1 (en) | DERIVATIVES OF N1-SULFONYL-5-FLUOROPYRIMIDINONE | |
| PE20150041A1 (en) | DERIVATIVES OF AMINO ACIDS FUNCTIONALIZED IN THE N TERMINAL, CAPABLE OF FORMING DRUG ENCAPSULATING MICROSPHERES | |
| PE20060691A1 (en) | SERINAMIDES REPLACED BY BENZOYL | |
| PE20060366A1 (en) | AMINOPYRIDINE DERIVATIVES AS DOPAMINE AGONISTS | |
| PE20090904A1 (en) | ARYLOXAZOLES REPLACED AS LIGANDS OF ADENOSINE A1 AND / OR A2b RECEPTORS | |
| PE20090226A1 (en) | PYRROLIDINAMIDES SUBSTITUTED AS INHIBITORS OF FACTOR Xa AND ITS PREPARATION | |
| PE20080608A1 (en) | CHEMICAL COMPOUNDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |